Infigratinib Represents New Option for FGFR2+ Cholangiocarcinoma
Sameek Roychowdhury, MD, PhD, contextualizes safety and efficacy data reported from a phase 2 study (NCT02150967) examining infigratinib (Truseltiq) in patients with FGFR2-positive cholangiocarcinoma, describes nuances to treatment with the agent, and sheds light on ongoing research efforts being made to further improve outcomes in this population.
Infigratinib Shows Promising Early Activity in FGFR2-Altered Cholangiocarcinoma
November 1st 2021The FGFR inhibitor infigratinib demonstrated promising clinical activity and a manageable safety profile in previously treated patients with locally advanced or metastatic cholangiocarcinoma whose tumors harbor FGFR2 gene fusions or rearrangement.
Roychowdhury Relays Impact of Recent Infigratinib Approval in FGFR+ Cholangiocarcinoma
November 29th 2021Sameek Roychowdhury, MD, PhD, discusses the pivotal phase 2 trial with infigratinib in FGFR-positive cholangiocarcinoma, the safety and efficacy achieved with infigratinib, and the next steps for this agent.
